Immucor Responding to FDA Warning Letter

NORCROSS, Ga. (Map) - NORCROSS, Ga., May 13 /PRNewswire-FirstCall/ -- Immucor, Inc., (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, announced today it is responding to an FDA warning letter posted today on the FDA website (http://www.fda.gov/foi/warning.htm).

Immucor CEO Dr. Gioacchino De Chirico said: "Our industry is highly regulated by the FDA, and we are subject to periodic inspection as a normal part of our business. We take our regulatory responsibilities very seriously and are working diligently to respond to the FDA as soon as possible. The FDA has not ordered the recall of any of our products, or placed any limitations on the manufacture or distribution of any of our products."

Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of our market segments.

For more information on Immucor, please visit our website at www.immucor.com .

Statements contained in this press release that are not statements of historical fact are "forward-looking statements" as that term is defined under federal securities laws, including, without limitation, all statements concerning Immucor's expectations, beliefs, intentions or strategies for the future. Forward-looking statements may be identified by words such as "plans," "expects," "believes," "anticipates," "estimates," "projects," "may," "will," "could", "should" and other words of similar meaning. Investors are cautioned not to place undue reliance on any forward-looking statements, and Immucor assumes no obligation to update any forward-looking statements. Immucor urges investors to consider the risks detailed in the Company's filings with the Securities and Exchange Commission.